Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

@article{Wang2021AntibodyRO,
  title={Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7},
  author={Pengfei Wang and Manoj S. Nair and Lihong Liu and Sho Iketani and Yang Luo and Yicheng Guo and Maple Wang and Jinghong Yu and Baoshan Zhang and Peter D. Kwong and Barney S. Graham and John R. Mascola and Jennifer Y. Chang and Michael T. Yin and Magdalena E. Sobieszczyk and Christos A. Kyratsous and Lawrence Shapiro and Zizhang Sheng and Yaoxing Huang and David D. Ho},
  journal={bioRxiv},
  year={2021}
}
The COVID-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Single and combination monoclonal antibody (mAb) therapeutics have received emergency use authorization1–3, with more in the pipeline4–7. Furthermore, multiple vaccine constructs have shown promise8, including two with ~95% protective efficacy against COVID-199,10. However, these interventions were directed… 
A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York
TLDR
Phylogenetic analyses of sequences in the database reveal that this B.1.526 variant is scattered in the Northeast of US, and its unique set of spike mutations may also pose an antigenic challenge for current interventions.
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
TLDR
Infectious SARS-CoV-2 B.1.617.2 spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes, which is believed to spread faster than the other versions.
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies
TLDR
It is suggested that several, but not all, of the antibody products in clinical use will lose efficacy against the B.1.
The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice
TLDR
Results indicate that the B.1.1-1.351 variant is pathogenic for the hACE2 mice, and leads more severe clinical symptoms than the prototype strain (IME-BJ05), which led only * 10% weight loss and no obvious clinical symptoms.
Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization
TLDR
The cryo-electron microscopy structure of a soluble prefusion-stabilized spike reveals the P.1.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position, with the functional impact of mutations appearing to arise from local changes instead of global conformational alterations.
Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37
TLDR
It is suggested that mRNA SARS-CoV-2 vaccines may remain effective against these viral variants of concern/interest and that spike binding antibody tests likely retain specificity in the face of evolving Sars-Cov-2 diversity.
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
TLDR
Some of the most promising broadly neutralizing antibodies obtained from plasma of patients that recovered from early variants of SARS-CoV-2 that may be effective against emerging new variants of the virus are reviewed.
...
...

References

SHOWING 1-10 OF 12 REFERENCES
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
TLDR
Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
TLDR
Two monoclonal antibodies isolated from a patient with COVID-19 are shown to interfere with SARS-CoV-2–receptor binding, and one displays potent action against this virus in vitro and in a rhesus macaque model.
Potently neutralizing and protective human antibodies against SARS-CoV-2
TLDR
An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
TLDR
In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11.
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
TLDR
Most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity, and rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
SARS-CoV-2 vaccines in development
TLDR
The development of vaccines against SARS-CoV-2 is reviewed, including an overview of the development process, the different types of vaccine candidate, and data from animal studies as well as phase I and II clinical trials in humans.
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
TLDR
The phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein in healthy adults found it induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100- μg dose in a phase 3 vaccine trial.
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
TLDR
Findings have important implications for those pursuing plasma therapy, isolation of neutralizing monoclonal antibodies, and determinants of immunity.
...
...